Ir al contenido

Anemia drepanocítica (pediatría)

Tratamiento de la anemia

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (abre una nueva ventana)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Fuente‎: Lancet Haematol. 2023 ;10(4):e261-71.

Indexado en‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (abre una nueva ventana)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (abre una nueva ventana)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Fuente‎: Acta Haematol 1995;94(3):128-34.

Indexado en‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (abre una nueva ventana)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (abre una nueva ventana)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Fuente‎: Haematologica 2006;91(8):1076-83.

Indexado en‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (abre una nueva ventana)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (abre una nueva ventana)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Fuente‎: J Obstet Gynaecol 2007;27(1):82-3.

Indexado en‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (abre una nueva ventana)